News >

FDA Approves Brentuximab Vedotin for Frontline CD30+ PTCL

Jason M. Broderick @jasoncology
Published: Friday, Nov 16, 2018

The FDA has approved brentuximab vedotin (Adcetris) for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma (PTCL).

No new safety signals emerged with brentuximab vedotin. The label for the antibody-drug conjugate does include a Boxed Warning regarding the risk of progressive multifocal leukoencephalopathy. Seattle Genetics and Takeda Pharmaceutical, the co-developers of brentuximab vedotin, will be presenting additional ECHELON-2 findings at the 2018 ASH Annual Meeting.

“The current standard of care for initial treatment of peripheral T-cell lymphoma is multi-agent chemotherapy. That treatment has not significantly changed in decades and is too often unsuccessful in leading to long-term remissions, underscoring the need for new treatments,” Steven Horwitz, MD, Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, said in a statement.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication